Meishan Huilong Pharmaceutical Technology Co., Ltd. announced that it will receive CNY 50 million in an equity round of funding on July 12, 2021. The transaction will include participation from returning investor ChengDu ShengNuo Biotec Co.,Ltd. to retain 100% stake in the company. The transaction has been approved by the eleventh meeting of the third board of directors and the seventh meeting of the third board of supervisors of investor.

Post-closing of the transaction, the registered capital of the company will increase from CNY 10 million to CNY 60 million.